Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$9.35 -2.6%	$7.13	$3.75 ▼ $11.40	$149.79M	2.79	101,336 shs	80,335 shs
CGEN Compugen	$1.64 -1.2%	$1.45	$1.13 ▼ $2.66	$146.35M	2.54	374,637 shs	173,625 shs
KYTX Kyverna Therapeutics	$3.22 -6.9%	$2.36	$1.78 ▼ $11.40	$139.17M	2.52	397,663 shs	288,515 shs
ONCY Oncolytics Biotech	$0.61 +5.4%	$0.50	$0.33 ▼ $1.53	$52.64M	0.71	622,955 shs	756,073 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	0.00%	-0.32%	+37.30%	+71.88%	+934,999,900.00%
CGEN Compugen	0.00%	-5.75%	+19.71%	-0.61%	-19.61%
KYTX Kyverna Therapeutics	0.00%	-5.01%	+47.71%	+28.80%	-76.56%
ONCY Oncolytics Biotech	0.00%	+68.89%	+21.53%	-2.72%	-40.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership
ACOG Alpha Cognition	1.7614 of 5 stars	3.5	0.0	2.9	0.8
CGEN Compugen	2.2282 of 5 stars	3.5	3.0	4.0	0.0
KYTX Kyverna Therapeutics	2.4772 of 5 stars	3.6	3.0	3.0	1.7
ONCY Oncolytics Biotech	1.462 of 5 stars	3.4	2.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOG Alpha Cognition	3.00	Buy	$20.00	113.90% Upside
CGEN Compugen	3.00	Buy	$4.00	143.90% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	474.53% Upside
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	612.72% Upside

Current Analyst Ratings Breakdown

Latest ONCY, CGEN, KYTX, and ACOG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	ACOG Alpha Cognition	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/3/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.00 ➝ $4.00
4/1/2025	KYTX Kyverna Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $20.00
3/31/2025	ACOG Alpha Cognition	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/25/2025	ACOG Alpha Cognition	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
3/18/2025	ACOG Alpha Cognition	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOG Alpha Cognition	$2.93M	51.15	N/A	N/A	($1.08) per share	-8.66
CGEN Compugen	$27.59M	5.30	N/A	N/A	$0.73 per share	2.25
KYTX Kyverna Therapeutics	$7.03M	19.80	N/A	N/A	N/A	∞
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOG Alpha Cognition	-$13.77M	-$1.20	N/A	∞	N/A	N/A	N/A	-344.17%	8/11/2025 (Estimated)
CGEN Compugen	-$18.75M	-$0.16	82.00	N/A	N/A	2.67%	2.62%	1.36%	8/5/2025 (Estimated)
KYTX Kyverna Therapeutics	-$60.37M	-$3.38	N/A	N/A	N/A	N/A	-51.12%	-37.91%	8/11/2025 (Estimated)
ONCY Oncolytics Biotech	-$20.56M	-$0.29	N/A	N/A	N/A	N/A	-141.15%	-84.73%	7/30/2025 (Estimated)

Latest ONCY, CGEN, KYTX, and ACOG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	-$0.08	-$0.02	-$0.08	$3.70 million	$2.28 million
5/15/2025	Q1 2025	ACOG Alpha Cognition	-$0.58	-$0.20	+$0.38	-$0.13	$0.50 million	$2.93 million
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
3/31/2025	Q4 2024	ACOG Alpha Cognition	-$0.48	-$0.51	-$0.03	-$0.51	N/A	N/A
3/27/2025	Q4 2024	KYTX Kyverna Therapeutics	-$0.87	-$0.88	-$0.01	-$0.88	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOG Alpha Cognition	N/A	1.50	1.50
CGEN Compugen	N/A	4.14	4.14
KYTX Kyverna Therapeutics	N/A	10.50	10.50
ONCY Oncolytics Biotech	N/A	2.99	2.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACOG Alpha Cognition	N/A
CGEN Compugen	12.22%
KYTX Kyverna Therapeutics	18.08%
ONCY Oncolytics Biotech	6.82%

Insider Ownership

Company	Insider Ownership
ACOG Alpha Cognition	14.00%
CGEN Compugen	9.50%
KYTX Kyverna Therapeutics	22.00%
ONCY Oncolytics Biotech	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOG Alpha Cognition	N/A	16.02 million	10.97 million	N/A
CGEN Compugen	70	89.24 million	80.76 million	Optionable
KYTX Kyverna Therapeutics	96	43.22 million	N/A	Optionable
ONCY Oncolytics Biotech	30	86.58 million	85.42 million	Not Optionable

ONCY, CGEN, KYTX, and ACOG Headlines

Recent News About These Companies

After Major Oncology Conference, All Eyes Turn to Industry Innovation

June 12 at 9:22 AM | prnewswire.co.uk

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

June 11, 2025 | prnewswire.com

Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by Brokerages

June 10, 2025 | americanbankingnews.com

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 23, 2025 | prnewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunome (IMNM), Oncolytics Biotech (ONCY) and Hookipa Pharma (HOOK)

May 18, 2025 | theglobeandmail.com

Jones Trading Downgrades Oncolytics Biotech (ONCY)

May 17, 2025 | msn.com

Oncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter Financial Results and Highlights Clinical Momentum

May 17, 2025 | finanznachrichten.de

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 14, 2025 | prnewswire.com

Oncolytics Biotech to Discuss Q1 2025 Financial Results on May 14

May 8, 2025 | tipranks.com

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

May 6, 2025 | prnewswire.com

Oncolytics Biotech, Inc. Common Shares (ONCY) Latest After Hours Trades

May 4, 2025 | nasdaq.com

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

April 24, 2025 | prnewswire.com

As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments

April 14, 2025 | baystreet.ca

Oncolytics Biotech Secures $20 Million Funding for Pelareorep Development

April 10, 2025 | tipranks.com

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

April 10, 2025 | prnewswire.com

Oncolytics Biotech® and Pelareorep Discussed During

April 10, 2025 | kxan.com

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

April 10, 2025 | prnewswire.com

Oncolytics price target lowered to $3 from $5 at Maxim

March 10, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, CGEN, KYTX, and ACOG Company Descriptions

Alpha Cognition NASDAQ:ACOG

$9.35 -0.25 (-2.60%)

As of 06/13/2025 04:00 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Compugen NASDAQ:CGEN

$1.64 -0.02 (-1.20%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.67 +0.03 (+1.77%)

As of 06/13/2025 06:26 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Kyverna Therapeutics NASDAQ:KYTX

$3.22 -0.24 (-6.94%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.34 +0.12 (+3.57%)

As of 06/13/2025 07:41 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Oncolytics Biotech NASDAQ:ONCY

$0.61 +0.03 (+5.39%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.59 -0.02 (-2.80%)

As of 06/13/2025 07:59 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time